New partnership aims to fast-track mRNA therapies from lab to clinic
News
Bluejay begins phase 3 trial of brelovitug for hepatitis D
First patient enrolled in AZURE-2 study comparing brelovitug to Hepcludex
Eisai unveils promising phase 1b data for narcolepsy drug E2086
Novel orexin receptor agonist shows potential to improve wakefulness
AlzeCure presents phase 2 data on ACD440 at NeuPSIG 2025
Topical TRPV1 antagonist shows promise in heat-induced neuropathic pain
Resolution Therapeutics doses first patient in EMERALD study of RTX001
Trial explores regenerative macrophage therapy for liver disease
eXmoor and Anthony Nolan partner to streamline cell therapy development
Collaboration offers end-to-end support from donor sourcing to manufacturing
FDA approves LEQEMBI IQLIK for maintenance dosing in early Alzheimer’s disease
New subcutaneous autoinjector offers at-home treatment option for patients
Lilly receives UK approval for pirtobrutinib in relapsed blood cancers
MHRA grants conditional authorisation for treatment targeting mantle cell lymphoma
Akiram advances trial of targeted radiotherapy for solid tumours
Swedish biotech company Akiram Therapeutics has announced significant progress in its first clinical trial of AKIR001,...
Coya Therapeutics to progress trial of ALS treatment upon FDA approval
The US Food and Drug Administration (FDA) has accepted an Investigational New Drug (IND) application from Coya...
Encare’s ERAS system gains Mayo Clinic qualification, strengthening global reach
Encare’s ERAS Interactive Audit System (EIAS) has earned qualification on the Mayo Clinic Platform_Solutions Studio –...
Johnny Cheng appointed as interim CEO of HUTCHMED
HUTCHMED has announced that Weiguo Su, CEO of the company, will take a leave of absence from his duties due to health...
Novartis blood disorder drug shows promise in late-stage trial
Novartis has reported that its experimental drug ianalumab met the primary goal in a phase 3 trial for primary immune...
Anne White to retire as head of Lilly Neuroscience after three decades at company
Eli Lilly and Company has announced that Anne White, executive vice president and president of Lilly Neuroscience,...
ANGLE partners with Myriad Genetics to explore blood-based cancer testing
ANGLE has announced a collaboration with Myriad Genetics to assess whether circulating tumour cell (CTC) DNA harvested from blood samples using ANGLE’s Parsortix system can be used alongside Myriad’s existing tissue-based diagnostic assays.
